Last reviewed · How we verify
HAIC of OXA
HAIC of OXA delivers oxaliplatin directly into the hepatic artery to achieve high local chemotherapy concentration in liver tumors while minimizing systemic exposure.
HAIC of OXA delivers oxaliplatin directly into the hepatic artery to achieve high local chemotherapy concentration in liver tumors while minimizing systemic exposure. Used for Hepatocellular carcinoma (HCC), Liver metastases from colorectal cancer.
At a glance
| Generic name | HAIC of OXA |
|---|---|
| Also known as | Oxaliplatin |
| Sponsor | Sun Yat-sen University |
| Drug class | Platinum-based chemotherapy (regional delivery) |
| Target | DNA (via platinum-DNA adduct formation) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Hepatic arterial infusion chemotherapy (HAIC) is a regional delivery technique that administers oxaliplatin (a platinum-based chemotherapy agent) directly into the hepatic artery supplying liver tumors. This approach concentrates the drug at the tumor site while reducing systemic toxicity. Oxaliplatin works by forming DNA adducts that inhibit DNA replication and transcription, leading to cancer cell death.
Approved indications
- Hepatocellular carcinoma (HCC)
- Liver metastases from colorectal cancer
Common side effects
- Hepatotoxicity
- Neutropenia
- Thrombocytopenia
- Nausea and vomiting
- Peripheral neuropathy
- Catheter-related complications
Key clinical trials
- The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases (PHASE2)
- Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (PHASE2)
- Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma (PHASE2)
- Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial (PHASE3)
- Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC (PHASE2)
- HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC (PHASE3)
- Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection (PHASE2, PHASE3)
- A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HAIC of OXA CI brief — competitive landscape report
- HAIC of OXA updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI